Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 2:47 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1321–1344 of 18,748 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Phase I Clear all

Conditions: Squamous Cell Carcinoma of the Head and Neck
Interventions: Pazopanib, Cetuximab; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Small Cell Lung Cancer and Breast Cancer
Interventions: Satoreotide tetraxetan, Satoreotide trizoxetan; Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Epilepsy, Dravet Syndrome, Lennox-Gastaut Syndrome
Interventions: TAK-935, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 2 Years to 17 Years
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 15
States / cities: Phoenix, Arizona • Los Angeles, California • Aurora, Colorado + 12 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: becatecarin, oxaliplatin, pharmacological study; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Advanced Solid Tumor, NSCLC, CRC
Interventions: JAB-21822 (KRAS G12C inhibitor), Cetuximab (EGFR inhibitor); Drug
Lead sponsor: Jacobio Pharmaceuticals Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 4
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more

Conditions: Obesity, Overweight
Interventions: LY4329090, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 184 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Daytona Beach, Florida • Dallas, Texas

Conditions: Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, Refractory B-Cell Lymphoma, MALT Lymphoma
Interventions: PSB202; Drug
Lead sponsor: Qilu Puget Sound Biotherapeutics (dba Sound Biologics); Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Louisville, Kentucky • New York, New York

Conditions: Advanced Solid Tumor
Interventions: STX-003, KEYTRUDA®; Biological
Lead sponsor: Strand Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 3
States / cities: Scottsdale, Arizona • Boston, Massachusetts • Nashville, Tennessee

Conditions: Advanced Solid Tumors
Interventions: ABT-348, ABT-348 and carboplatin, ABT-348 and docetaxel; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 2
States / cities: Chicago, Illinois • Houston, Texas

Conditions: Lymphoma
Interventions: RevM10 gene, RevM10/polAS gene, in vitro-treated peripheral blood stem cell transplantation, peripheral blood stem cell transplantation; Biological · Procedure
Lead sponsor: Systemix; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1998
U.S. locations: 6
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 2 more

Conditions: Advanced Solid Tumors
Interventions: MLN4924, Fluconazole, Itraconazole, Docetaxel, Carboplatin, Paclitaxel; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 4
States / cities: Atlanta, Georgia • St Louis, Missouri • Nashville, Tennessee + 1 more

Conditions: Non-Hodgkin Lymphoma
Interventions: Cyclophosphamide, Fludarabine, CAR-T Cells; Drug · Biological
Lead sponsor: Benjamin Tomlinson; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2036
U.S. locations: 2
States / cities: St Louis, Missouri • Cleveland, Ohio

Conditions: Breast Cancer
Interventions: MAB HER 2 (HERCEPTIN); Biological
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Genital Herpes Simplex Type 2
Interventions: BNT163, Placebo; Biological · Other
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 318 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 6
States / cities: Tempe, Arizona • Chicago, Illinois • Raleigh, North Carolina + 3 more

Conditions: Metastatic Breast Cancer (MBC)
Interventions: Palbociclib, Bicalutamide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2026
U.S. locations: 5
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 2 more

Conditions: Sickle Cell Disease
Interventions: ITU512, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 12 Years to 55 Years
Enrollment: 161 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2030
U.S. locations: 9
States / cities: Birmingham, Alabama • Miami, Florida • Boston, Massachusetts + 6 more

Conditions: HIV-1-infection
Interventions: SAR441236, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 23
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 17 more

Conditions: Psychological Effects of Study Drug
Interventions: Lactose (inactive placebo), midomafetamine HCl; Drug
Lead sponsor: Resilient Pharmaceuticals; Industry
Eligibility: 21 Years and older
Enrollment: 107 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2022
U.S. locations: 3
States / cities: Boulder, Colorado • Santa Fe, New Mexico • Mt. Pleasant, South Carolina

Conditions: Metastatic Epidural Spinal Cord Compression
Interventions: Stereotactic Radiosurgery (SSRS), Questionnaires; Procedure · Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Fanconi Anemia, Anemia, Hypoplastic, Congenital, Congenital Bone Marrow Failure Syndromes, Bone Marrow Failure Disorders, Genetic Diseases, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA Repair-Deficiency Disorders, Cancer Predisposition Syndrome
Interventions: IUHSCT for FA-affected fetuses; Biological
Lead sponsor: Agnieszka Czechowicz; Other
Eligibility: Not listed
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2028 – 2033
U.S. locations: 2
States / cities: San Francisco, California • Stanford, California

Conditions: Liver Transplantation, Immune Tolerance, Immune Tolerance/Drug Effects, Graft Survival, Hematopoietic Stem Cell, Chimerism, Immunosuppression After Liver Transplantation, Immunosuppression Disorders, End Stage Liver Disease
Interventions: Donor Hematopoietic Stem and Progenitor Cell Infusion; Biological
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Enterotoxigenic E. Coli (ETEC) Infection
Interventions: ACE527 vaccine, Placebo vaccine; Biological
Lead sponsor: TD Vaccines A/S; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Advanced Solid Tumors
Interventions: BMS-986490, Bevacizumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 4
States / cities: Los Angeles, California • Grand Rapids, Michigan • Hackensack, New Jersey + 1 more

Conditions: Endothelial Dysfunction, Metabolic Syndrome, Chronic Inflammation
Interventions: UCMSCs, BMMSCs, Placebo; Biological · Other
Lead sponsor: Joshua M Hare; Other
Eligibility: 21 Years to 95 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Pazopanib Plus Cetuximab for Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)

Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 (OV935) as an Adjunctive Therapy in Pediatric Participants With Developmental and/or Epileptic Encephalopathies

Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy

PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies

Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

ABT-348 as Monotherapy or Combination With Carboplatin or Docetaxel to Treat Advanced Solid Tumors

Gene Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With HIV-Related Non-Hodgkin's Lymphoma

Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors

AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma

Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity

A Clinical Trial in Healthy Volunteers and Volunteers With Recurrent Genital Herpes to Study the Safety, Tolerability, and Immune Responses After Vaccination With an Investigational Vaccine Designed to Prevent Genital Herpes Lesions

Palbociclib in Combination With Bicalutamide for the Treatment of AR(+) Metastatic Breast Cancer (MBC)

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

Pharmacokinetics and Safety of SAR441236

Psychological Effects of Methylenedioxymethamphetamine (MDMA) When Administered to Healthy Volunteers

Single Session Spine Stereotactic Radiosurgery in Metastatic Epidural Spinal Cord Compression

Prenatal Transplantation for Fetuses With Fanconi Anemia

Immune Tolerance Induction After Liver Transplantation

ACE527 Safety and Immunogenicity Study

A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid Tumors

Infusion of Umbilical Cord Versus Bone Marrow Derived Mesenchymal Stem Cells to Evaluate Cytokine Suppression.